David R Corey

List of Publications by Year in Descending Order

133 papers	9,563 citations	50 h-index	96 g-index
139 ext. papers	10,702 ext. citations	10.7 avg, IF	6.74 L-index

#	Paper	IF	Citations
133	Difficulties translating antisense-mediated activation of Frataxin expression from cell culture to mice.. *RNA Biology*, **2022**, 19, 364-372	4.8	1
132	Argonaute and TNRC6, partners in RNAi **2022**, 17-36		
131	Challenges and Opportunities for Nucleic Acid Therapeutics.. *Nucleic Acid Therapeutics*, **2021**,	4.8	5
130	Targeting 3Uand 5Uuntranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. *Nucleic Acids Research*, **2021**, 49, 11560-11574	20.1	0
129	Impact of scaffolding protein TNRC6 paralogs on gene expression and splicing. *Rna*, **2021**, 27, 1004-1016	5.8	2
128	Argonaute binding within human nuclear RNA and its impact on alternative splicing. *Rna*, **2021**, 27, 991-1003	5.8	4
127	Reexamining assumptions about miRNA-guided gene silencing.. *Nucleic Acids Research*, **2021**,	20.1	6
126	Analyzing pre-symptomatic tissue to gain insights into the molecular and mechanistic origins of late-onset degenerative trinucleotide repeat disease. *Nucleic Acids Research*, **2020**, 48, 6740-6758	20.1	7
125	Argonaute binding within 3Uuntranslated regions poorly predicts gene repression. *Nucleic Acids Research*, **2020**, 48, 7439-7453	20.1	8
124	The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy. *Nucleic Acid Therapeutics*, **2020**, 30, 67-70	4.8	50
123	Trinucleotide Repeat-Targeting dCas9 as a Therapeutic Strategy for FuchsUEndothelial Corneal Dystrophy. *Translational Vision Science and Technology*, **2020**, 9, 47	3.3	4
122	Limits of using oligonucleotides for allele-selective inhibition at trinucleotide repeat sequences - targeting the CAG repeat within ataxin-1. *Nucleosides, Nucleotides and Nucleic Acids*, **2020**, 39, 185-194	1.4	1
121	Progress towards drug discovery for FriedreichUs Ataxia: Identifying synthetic oligonucleotides that more potently activate expression of human frataxin protein. *Bioorganic and Medicinal Chemistry*, **2020**, 28, 115472	3.4	7
120	Quantitative Studies of Muscleblind Proteins and Their Interaction With TCF4 RNA Foci Support Involvement in the Mechanism of FuchsUDystrophy **2019**, 60, 3980-3991		8
119	Duplex RNAs and ss-siRNAs Block RNA Foci Associated with FuchsUEndothelial Corneal Dystrophy. *Nucleic Acid Therapeutics*, **2019**, 29, 73-81	4.8	7
118	Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs. *Nucleic Acid Therapeutics*, **2019**, 29, 116-122	4.8	24
117	Efficient electroporation of neuronal cells using synthetic oligonucleotides: identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression. *Rna*, **2019**, 25, 1118-1129	5.8	7

116	Expression of TNRC6 (GW182) Proteins Is Not Necessary for Gene Silencing by Fully Complementary RNA Duplexes. *Nucleic Acid Therapeutics*, **2019**, 29, 323-334	4.8	7
115	Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat. *Nucleic Acid Therapeutics*, **2018**, 28, 23-33	4.8	26
114	Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and mis-splicing in FuchsU dystrophy. *Human Molecular Genetics*, **2018**, 27, 1015-1026	5.6	30
113	Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. *Nucleic Acids Research*, **2018**, 46, 1584-1600	20.1	345
112	Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2850-2855	2.9	14
111	The Requirement for GW182 Scaffolding Protein Depends on Whether Argonaute Is Mediating Translation, Transcription, or Splicing. *Biochemistry*, **2018**, 57, 5247-5256	3.2	9
110	c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA. *Cell Chemical Biology*, **2017**, 24, 141-148	8.2	22
109	Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. *Nature Neuroscience*, **2017**, 20, 497-499	25.5	136
108	Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. *Nucleic Acid Therapeutics*, **2017**, 27, 87-94	4.8	16
107	Human GW182 Paralogs Are the Central Organizers for RNA-Mediated Control of Transcription. *Cell Reports*, **2017**, 20, 1543-1552	10.6	23
106	Non-coding RNAs as drug targets. *Nature Reviews Drug Discovery*, **2017**, 16, 167-179	64.1	492
105	RNA-Mediated Gene Activation: Identifying a Candidate RNA for Preclinical Development. *Advances in Experimental Medicine and Biology*, **2017**, 983, 161-171	3.6	3
104	HP1BP3, a Chromatin Retention Factor for Co-transcriptional MicroRNA Processing. *Molecular Cell*, **2016**, 63, 420-32	17.6	21
103	Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-Reply. *JAMA Neurology*, **2016**, 73, 1502-1503	17.2	1
102	Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells. *Rna*, **2016**, 22, 1085-98	5.8	30
101	Regulation of mammalian transcription and splicing by Nuclear RNAi. *Nucleic Acids Research*, **2016**, 44, 524-37	20.1	67
100	Pathogenic C9ORF72 Antisense Repeat RNA Forms a Double Helix with Tandem C:C Mismatches. *Biochemistry*, **2016**, 55, 1283-6	3.2	24
99	Activating frataxin expression by repeat-targeted nucleic acids. *Nature Communications*, **2016**, 7, 10606	17.4	55

98	Argonaute 2-dependent Regulation of Gene Expression by Single-stranded miRNA Mimics. *Molecular Therapy*, **2016**, 24, 946-55	11.7	32
97	Synthetic Nucleic Acids and Treatment of Neurological Diseases. *JAMA Neurology*, **2016**, 73, 1238-1242	17.2	4
96	Design and bioinformatics analysis of genome-wide CLIP experiments. *Nucleic Acids Research*, **2015**, 43, 5263-74	20.1	57
95	Modulation of Splicing by Single-Stranded Silencing RNAs. *Nucleic Acid Therapeutics*, **2015**, 25, 113-20	4.8	14
94	Reduced Expression of Argonaute 1, Argonaute 2, and TRBP Changes Levels and Intracellular Distribution of RNAi Factors. *Scientific Reports*, **2015**, 5, 12855	4.9	19
93	Intramolecular circularization increases efficiency of RNA sequencing and enables CLIP-Seq of nuclear RNA from human cells. *Nucleic Acids Research*, **2015**, 43, e75	20.1	11
92	Stepping toward therapeutic CRISPR. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15536-7	11.5	7
91	Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. *Chemistry and Biology*, **2015**, 22, 1505-1511		17
90	Identification and validation of miRNA target sites within nontraditional miRNA targets. *Methods in Molecular Biology*, **2015**, 1206, 53-67	1.4	2
89	Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading. *Nature Protocols*, **2014**, 9, 2045-60	18.8	111
88	Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. *Biochemistry*, **2014**, 53, 4510-8	3.2	26
87	Effect of 2⊍O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells. *Artificial DNA, PNA & XNA*, **2014**, 5, e1146391		4
86	Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. *Nucleic Acid Therapeutics*, **2014**, 24, 199-209	4.8	15
85	RNAi factors are present and active in human cell nuclei. *Cell Reports*, **2014**, 6, 211-21	10.6	253
84	Digital quantitation of potential therapeutic target RNAs. *Nucleic Acid Therapeutics*, **2013**, 23, 188-94	4.8	47
83	Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions. *Biochemistry*, **2013**, 52, 9329-38	3.2	16
82	Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter. *ACS Chemical Biology*, **2013**, 8, 122-6	4.9	22
81	ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. *Nucleic Acids Research*, **2013**, 41, 9570-83	20.1	36

(2010-2013)

80	RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. *Nucleic Acids Research*, **2013**, 41, 8788-801	20.1	30
79	Promoter RNA links transcriptional regulation of inflammatory pathway genes. *Nucleic Acids Research*, **2013**, 41, 10086-109	20.1	144
78	Allele-selective inhibition of trinucleotide repeat genes. *Drug Discovery Today*, **2012**, 17, 443-50	8.8	27
77	Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. *Cell*, **2012**, 150, 895-908	56.2	215
76	Silencing disease genes in the laboratory and the clinic. *Journal of Pathology*, **2012**, 226, 365-79	9.4	267
75	Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. *Nucleic Acid Therapeutics*, **2012**, 22, 3-16	4.8	49
74	Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. *Nucleic Acids Research*, **2012**, 40, 1240-50	20.1	58
73	Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway. *Nucleic Acids Research*, **2012**, 40, 11270-80	20.1	30
72	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5202-5	2.9	10
71	Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. *Nucleic Acids Research*, **2011**, 39, 5682-91	20.1	150
70	Transcriptional regulation by miRNA mimics that target sequences downstream of gene termini. *Molecular BioSystems*, **2011**, 7, 2383-8		25
69	Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. *Journal of the American Chemical Society*, **2011**, 133, 8404-7	16.4	33
68	Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. *Biological Chemistry*, **2011**, 392, 315-25	4.5	43
67	Transcriptional regulation by small RNAs at sequences downstream from 3Ugene termini. *Nature Chemical Biology*, **2010**, 6, 621-9	11.7	89
66	Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. *Nucleic Acids Research*, **2010**, 38, 7736-48	20.1	136
65	Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. *Nucleic Acids Research*, **2010**, 38, 5242-59	20.1	37
64	Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. *Biochemistry*, **2010**, 49, 10166-78	3.2	116
63	Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. *Chemistry and Biology*, **2010**, 17, 1344-55		71

62	Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. *Chemistry and Biology*, **2010**, 17, 1183-8		79
61	Clinical status of duplex RNA. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3203-7	2.9	53
60	Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer. *Prostate*, **2010**, 70, 616-29	4.2	5
59	The puzzle of RNAs that target gene promoters. *ChemBioChem*, **2009**, 10, 1135-9	3.8	15
58	Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. *Nature Biotechnology*, **2009**, 27, 478-84	44.5	193
57	Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. *Annals of the New York Academy of Sciences*, **2009**, 1175, 24-31	6.5	38
56	Telomeres and telomerase: from discovery to clinical trials. *Chemistry and Biology*, **2009**, 16, 1219-23		40
55	Predicting potential miRNA target sites within gene promoters. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3791-4	2.9	56
54	Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6181-4	2.9	17
53	Antisense transcripts are targets for activating small RNAs. *Nature Structural and Molecular Biology*, **2008**, 15, 842-8	17.6	239
52	Recognition of chromosomal DNA inside cells by locked nucleic acids. *Biochemistry*, **2008**, 47, 13147-9	3.2	25
51	Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. *Biochemistry*, **2007**, 46, 7572-80	3.2	31
50	Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA. *Biochemistry*, **2007**, 46, 7581-9	3.2	78
49	Chemical modification: the key to clinical application of RNA interference?. *Journal of Clinical Investigation*, **2007**, 117, 3615-22	15.9	219
48	RNA learns from antisense **2007**, 3, 8-11		77
47	Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. *Nature Chemical Biology*, **2007**, 3, 166-73	11.7	402
46	Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. *Molecular Endocrinology*, **2006**, 20, 2724-33		213
45	Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. *Urologic Oncology: Seminars and Original Investigations*, **2006**, 24, 141-51	2.8	14

44	Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs. *Nature Protocols*, **2006**, 1, 436-43	18.8	37
43	Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. *Nature Structural and Molecular Biology*, **2006**, 13, 787-92	17.6	270
42	Peptide Nucleic Acids **2006**, 236-242		
41	Calcium liberates PNAs from endosomes. *Chemistry and Biology*, **2005**, 12, 864-5		1
40	Recognition of chromosomal DNA in human cells by peptide nucleic acids and small duplex RNAs. *Annals of the New York Academy of Sciences*, **2005**, 1058, 16-25	6.5	2
39	Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. *Nature Chemical Biology*, **2005**, 1, 210-5	11.7	143
38	Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. *Nature Chemical Biology*, **2005**, 1, 216-22	11.7	142
37	Regulating mammalian transcription with RNA. *Trends in Biochemical Sciences*, **2005**, 30, 655-8	10.3	27
36	Peptide nucleic acids: Cellular delivery and recognition of DNA and RNA targets. *International Journal of Peptide Research and Therapeutics*, **2005**, 10, 347-352	2.1	
35	Challenges for RNAi in vivo. *Trends in Biotechnology*, **2004**, 22, 390-4	15.1	88
34	Biodistribution of phosphodiester and phosphorothioate siRNA. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 1139-43	2.9	222
33	Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids. *Biochemistry*, **2004**, 43, 1921-7	3.2	23
32	Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. *Biochemistry*, **2004**, 43, 14340-7	3.2	67
31	Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugates. *Methods in Molecular Biology*, **2004**, 283, 197-206	1.4	3
30	Validating Bioluminescence Imaging as a High-Throughput, Quantitative Modality for Assessing Tumor Burden. *Molecular Imaging*, **2004**, 3, 153535002004031	3.7	
29	Peptide nucleic acids: Cellular delivery and recognition of DNA and RNA targets. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 347-352		
28	Imaging gene expression using oligonucleotides and peptide nucleic acids. *Journal of Cellular Biochemistry*, **2003**, 90, 437-42	4.7	9
27	RNA interference in mammalian cells by chemically-modified RNA. *Biochemistry*, **2003**, 42, 7967-75	3.2	466

26	Peptide nucleic acids: Cellular delivery and recognition of DNA and RNA targets. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 347-352	2.1	5
25	Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. *Cancer Research*, **2003**, 63, 5917-25	10.1	42
24	Telomerase inhibition, oligonucleotides, and clinical trials. *Oncogene*, **2002**, 21, 631-7	9.2	86
23	Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. *Nucleic Acids Research*, **2002**, 30, 5160-7	20.1	86
22	Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2ʹO-methoxyethyl oligonucleotides. *Journal of Medicinal Chemistry*, **2002**, 45, 5423-5	8.3	19
21	Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. *Biochemistry*, **2002**, 41, 9973-81	3.2	84
20	Novel antisense and peptide nucleic acid strategies for controlling gene expression. *Biochemistry*, **2002**, 41, 4503-10	3.2	230
19	Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntingtonʹs disease with an antisense radiopharmaceutical and drug-targeting technology. *Journal of Nuclear Medicine*, **2002**, 43, 948-56	8.9	43
18	Liver cell specific targeting of peptide nucleic acid oligomers. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1269-72	2.9	46
17	Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. *Chemistry and Biology*, **2001** , 8, 1-7		461
16	The structure of a Michaelis serpin-protease complex. *Nature Structural Biology*, **2001**, 8, 979-83		125
15	Morpholino antisense oligonucleotides: tools for investigating vertebrate development. *Genome Biology*, **2001**, 2, REVIEWS1015	18.3	110
14	Synthesis, analysis, purification, and intracellular delivery of peptide nucleic acids. *Methods*, **2001**, 23, 97-107	4.6	52
13	Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length. *Biochemistry*, **2001**, 40, 53-64	3.2	139
12	Strand invasion by mixed base PNAs and a PNA-peptide chimera. *Nucleic Acids Research*, **2000**, 28, 3332-8	20.1	55
11	Strand invasion by DNA-peptide conjugates and peptide nucleic acids. *Nucleic Acids Symposium Series*, **1999**, 141-2		1
10	Cellular delivery of peptide nucleic acids and inhibition of human telomerase. *Chemistry and Biology* , **1999**, 6, 343-51		142
9	Telomerase inhibition by peptide nucleic acids reverses ʹimmortalityʹof transformed human cells. *Oncogene*, **1999**, 18, 6191-200	9.2	130

8	Automated synthesis of peptide nucleic acids and peptide nucleic acid-peptide conjugates. *Analytical Biochemistry*, **1999**, 268, 401-4	3.1	45
7	Rules for Strand Invasion by Chemically Modified Oligonucleotides. *Journal of the American Chemical Society*, **1999**, 121, 2012-2020	16.4	27
6	Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. *Biochemistry*, **1997**, 36, 11873-80	3.2	92
5	Synthesis and membrane permeability of PNA-peptide conjugates. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 3001-3006	2.9	94
4	Specific and nonspecific inhibition of transcription by DNA, PNA, and phosphorothioate promoter analog duplexes. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 2897-2900	2.9	39
3	Inhibition of human telomerase activity by peptide nucleic acids. *Nature Biotechnology*, **1996**, 14, 615-9	44.5	314
2	Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge. *Nature Biotechnology*, **1996**, 14, 1700-4	44.5	74
1	Targeting peptide nucleic acid-protein conjugates to structural features within duplex DNA. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 437-45	3.4	37